HOOKIPA Pharma is a biopharmaceutical company developing a class of immunotherapeutics based on its proprietary arenavirus platform that is designed to target and amplify a T cell and immune response to disease. Co. is building a proprietary immuno-oncology pipeline by targeting oncoviral cancer antigens, self-antigens and antigens. Co.'s lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus 16-positive cancers in a Phase 1/2 clinical trial. Co.'s non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is a potential compound in a Phase 2 clinical trial for kidney transplant patients. The HOOK YTD return is shown above.
The YTD Return on the HOOK YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether HOOK YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the HOOK YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|